Investing.com - HCW Biologics (NASDAQ: HCWB) reported third quarter EPS of $-0.14, $0.01 worse than the analyst estimate of $-0.13. Revenue for the quarter came in at $853.1K versus the consensus estimate of $600K.
HCW Biologics's stock price closed at $1.41. It is down -30.20% in the last 3 months and down -35.91% in the last 12 months.
HCW Biologics saw positive EPS revisions and negative EPS revisions in the last 90 days. See HCW Biologics's stock price’s past reactions to earnings here.
According to InvestingPro, HCW Biologics's Financial Health score is "weak performance".
Check out HCW Biologics's recent earnings performance, and HCW Biologics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar